Payden & Rygel’s GSK GSK Stock Holding History

Payden & Rygel’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-1,680	Closed	-$87K	–	153
2015 Q2	$87K	Hold	1,680	–	–	0.01%	97
2015 Q1	$97K	Hold	1,680	–	–	0.01%	98
2014 Q4	$90K	Hold	1,680	–	–	0.02%	93
2014 Q3	$97K	Sell	1,680 -50,240	-97%	-$3.08M	0.02%	93
2014 Q2	$3.47M	Buy	51,920 +17,920	+53%	+$1.21M	0.88%	52
2014 Q1	$2.27M	Hold	34,000	–	–	0.88%	54
2013 Q4	$2.27M	Hold	34,000	–	–	0.77%	52
2013 Q3	$2.13M	Sell	34,000 -39,920	-54%	-$2.57M	0.76%	53
2013 Q2	$4.62M	Buy	+73,920	New	+$4.69M	1.8%	16

Other funds holding GSK

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Payden & Rygel's GSK Position: Q3 2015 in Review

Payden & Rygel sold out of GSK (GSK) in Q3 2015, closing a stake of 1,680 shares — an estimated $87K sold.

Payden & Rygel first reported a position in GSK in Q2 2013 and held it in 9 quarters. The position peaked at $4.62M in Q2 2013. 706 funds tracked by Wall St. Rank hold GSK as of Q3 2015.

Payden & Rygel reported no remaining GSK position as of Q3 2015 after selling out during the quarter.
Payden & Rygel sold 1,680 GSK shares in Q3 2015, an estimated $87K.
Payden & Rygel first reported a position in GSK in Q2 2013 and held it in 9 quarters.
Payden & Rygel's GSK position peaked at $4.62M in Q2 2013.
706 funds tracked by Wall St. Rank held GSK as of Q3 2015.

Based on Payden & Rygel's 13F filing for Q3 2015, filed 2 Nov 2015.